MarketInOut Stock Screener Log In | Sign Up
 

Artiva Biotherapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/11/2026
Artiva Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization499.66 mln
Float34.30 mln
Earnings Date11/18/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

10 / 100
Significantly lagging

Debt / Equity

0.03
Debt-free

ROE

-55.14
Deeply negative

ROA

-49.16
Deeply negative

Business Description

Artiva Biotherapeutics is a San Diego-based clinical-stage company, founded in 2019, that develops treatments using natural killer cells ? a type of immune cell the body uses to fight disease. Its main therapy, AlloNK, is a ready-to-use cell treatment being studied for a range of autoimmune conditions as well as certain blood cancers. The company is also advancing two additional cell-based treatments aimed at solid tumors, including breast, gastric, and bladder cancers, and at other blood-related cancers.

Key Fundamentals

EPS-3.23
ROE-55.14
ROIC-445
ROA-49.16
EBITDA, mln-93.46
EV / EBITDA-2.16
EV / EBIT-2.10

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio5.84
Short % of Float5.35

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -8.18% 12 / 100   
1 Month -11.36% 18 / 100   
2 Months 33.07% 95 / 100   
6 Months 51.41% 93 / 100   
1 Year 279% 99 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us